Rare Cannabinoids Slowly Revolutionizing the Pharmaceutical Industry

Cannabis is now legal for recreational use in 18 states and legal for medicinal use in 36 states across the country. As the plant gains more popularity, so do some of its products, the most popular ones being THC and CBD, which are cannabinoids.

Cannabinoids are compounds found in the cannabis plant. Other cannabinoids found in the cannabis plant include tetrahydrocannabivarin (“THCV”), cannabinol (“CBN”) and cannabigerol (“CBG”), among others. These rare cannabinoids don’t possess THC’s psychoactive properties and have been found to be more potent in comparison to CBD. Forecasts show that by the year 2029, the international market for cannabinoid-based pharmaceuticals will be valued at $50 billion.

Rare cannabinoids are set to revolutionize the pharmaceutical industry given the multitude of potential medical benefits they possess and the lack of adverse effects induced by present medications.

What effect do these compounds have on the body?

The endocannabinoid system (“ECS”) is made up of three primary components, namely the endocannabinoids, enzymes and receptors. It is through this system that cannabinoids interact with our bodies and produce their beneficial effects.

The ECS system is known to play a crucial role in the regulation of various processes and functions including fertility, production, memory, mood, appetite and sleep. Its functions also contribute to the stability of the internal environment of the body.

Both endocannabinoids and rare exogenous cannabinoids are important to human health given that they tap into the endocannabinoid system.

How will these compounds change the pharmaceutical industry?

Prior studies have demonstrated the effectiveness of cannabinoids against various indications, with more than 50 trials on these compounds providing a lot of data on their health benefits. For instance, clinical and preclinical studies have proposed a possible value for CBD in various neuropsychiatric disorders, including schizophrenia, anxiety and epilepsy.

Rare cannabinoids such as THCA, THCV, CBN and CBG have also demonstrated that they possess major health benefits. For example, clinical trials on THCV have found that it can be useful in managing pain and swelling, anxiety and diabetes while CBG has been found to have the potential to help fight nausea, pain and inflammation.

In addition to this, a new biosynthesis production technique has enabled cannabinoids to be produced at 75% to 90% less cost than the present market. This patented method has allowed the production of rare pharmaceutical-grade cannabinoids, which are considerably cheaper and, in a way, minimally affect the environment. This method also produces the most effective and safest cannabinoids.

This and many other cannabinoid benefits yet to be discovered prove just how beneficial these compounds are and the impact they could have on the pharmaceutical industry as well as the healthcare sector at large.

It would be interesting to see how the use of precise dose-measuring devices such as those made by RYAH Group Inc. (CSE: RYAH) might help researchers studying rare cannabinoids and their reported therapeutic benefits.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.